{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-045515","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2023-12-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.911851+00:00","generated_at":"2026-06-07T09:46:09.802325+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Dare Bioscience reports positive Phase 1 topline results for DARE-PDM1 in primary dysmenorrhea","bullets":["DARE-PDM1 (vaginal diclofenac hydrogel) was well-tolerated; no serious AEs; 85% of AEs mild.","Vaginal fluid PK showed dose proportionality and retention in vaginal canal for 24 hours.","Exploratory efficacy: statistically significant reduction in pelvic/vaginal and lower back pain for 1% DARE-PDM1 vs placebo.","Plasma PK data pending; company plans continued development and 505(b)(2) regulatory pathway.","DARE-PDM1 has potential as first-in-category vaginal treatment for primary dysmenorrhea; market estimated $13B in 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-045515","json":"https://secwatch.observer/filing/0001493152-23-045515.json","markdown":"https://secwatch.observer/filing/0001493152-23-045515.md","text":"https://secwatch.observer/filing/0001493152-23-045515.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223045515/0001493152-23-045515-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000149315223045515/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T09:46:09.802325+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}